Enhanced Bioavailability and Higher Uptake of Brain-Targeted Surface Engineered Delivery System of Naringenin developed as a Therapeutic for Autism Spectrum Disorder
Authors:
- 1 February 2023
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 20 (2) , 158-182
Abstract
Background: Neuroinflammation resulting from oxidative and nitrosative stress is associated with various neurological disorders and involves the generation of pro-inflammatory cytokines and microglial activation. Dietary phytochemicals are safer and more valuable adjunct neurotherapeutic agents which can be added to the therapeutic regimen. These compounds provide neuroprotection by the modulation of various signaling pathways. Introduction: Naringenin (NGN) is a phytochemical having low oral bioavailability because of poor solubility, and adding to this limitation is enhanced efflux by P-glycoprotein transporters in neuroinflammatory diseases. Methods: Hence, as a solution for these limitations, naringenin encapsulated poly-lactic-co-glycolic acid (PLGA) nanocarriers were developed using the nanoprecipitation technique and coated with 1% glutathione (GSH) and 1% Tween 80 to enhance brain delivery. Results: Coated and uncoated NGN-PLGA nanoparticles (NGN-PLGA-NPs) were spherical, monodispersed, stable, and non-toxic, with a particle size of less than 200 nm. They had negative zeta-potential values, 80% entrapment efficiency, and sustained drug release of 81.8% (uncoated), 80.13%, and 78.43% (coated) in 24 hours. FT-IR, DSC, PXRD, and NMR confirmed the drug encapsulation and coating over nanoparticles. In-vivo brain uptake showed greater fluorescence intensity of the coated nanoparticles in the brain than uncoated nanoparticles. In addition, there was a 2.33-fold increase in bioavailability after coating compared to naringenin suspension and enhanced brain uptake. Conclusion: Present studies indicate sustained and targeted brain delivery of naringenin via the ligandcoated delivery system by inhibiting enhanced P-glycoprotein (P-gp) efflux occurring in autism spectrum disorders due to neuroinflammation.Keywords
Funding Information
- SERB, Department of Science and Technology (SB/FT/LS-284/2012)
- All India Council of Technical Education (11-25/RIFD/CAYT/POL-II/2013-14)
- University Grants Commission (20-29(12)/2012(BSR))
This publication has 62 references indexed in Scilit:
- In vitro dissolution testing strategies for nanoparticulate drug delivery systems: recent developments and challengesDrug Delivery and Translational Research, 2013
- Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer's DiseasePLOS ONE, 2012
- Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA–PEG diblock copolymer nanospheres for ophthalmic flurbiprofen deliveryInternational Journal of Nanomedicine, 2012
- Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery CarrierPolymers, 2011
- Surface Engineered Poly(lactide-co-glycolide) Nanoparticles for Intracellular Delivery: Uptake and Cytotoxicity—A Confocal Raman Microscopic StudyBiomacromolecules, 2010
- Preparation of Monodisperse Biodegradable Polymer Microparticles Using a Microfluidic Flow‐Focusing Device for Controlled Drug DeliverySmall, 2009
- Neuroinflammation Activates Mdr1b Efflux Transport Through NFκB: Promoter Analysis in BBB EndotheliaCellular Physiology and Biochemistry, 2008
- Apolipoprotein B–dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringeninHepatology, 2008
- Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brainBiomaterials, 2004
- Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat.Journal of Clinical Investigation, 1990